Dassault Systemes Sees Double Digit growth in India on Strong Domestic Demand
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
French 3D software major Dassault Systemes is seeing double digit growth in India on the back of strong domestic demand from sectors like Manufacturing, Infrastructure, and Lifesciences. India is a key hub for the company with about 15 per cent of its 25,000 strong workforce based here.
"Though we don't declare the numbers, we have a good presence in India. India has been contributing significantly to our global revenue of about USD 6.7 billion. From 2020 onwards, we are growing in double digits driven by the domestic demand. We have seen growth in the automotive and infrastructure related projects," Deepak NG, Managing Director, Dassault Systemes India told Entrepreneur India.
In India, Dassault Systemes works with companies such as Mahindra & Mahindra, Ashok Leyland, L&T Hydrocarbon, Raphe, and Blumotiv, among others.
In the recent past, Dassault is witnessing increased adoption of technology in the manufacturing sector. "Earlier, many of these organizations had homegrown applications…but we have been seeing now that they want to have applications that are well established which actually helps them on optimization of their production plants, making machines interact with each other, etc.," said Deepak.
During the first quarter earnings, Dassault Systemes' revenue in the Americas increased by 7 per cent to represent 43 per cent of the software revenue. This growth acceleration is driven by Aerospace & Defense, Transport & Mobility, and High-Tech. Despite tariff uncertainty, Europe, representing 36 per cent of the software revenue, increased 1 per cent, led by good growth in Aerospace & Defense. In Asia, revenue increased 5 per cent driven by India, Southeast Asia, and Korea. Asia represented 22 per cent of the software revenue.
In India, though a majority of the revenue is driven by the large enterprises, there is a huge installation base in the MSME and startup segments.
"We are seeing a lot of traction from the startup segment whether it is drone manufacturing or EV battery…they are all leveraging our cloud successfully. So we have a dedicated team focusing on that to support startups with some new programs and initiatives, to help them with the right application based on their product design and development. So while large accounts give us more growth because of the size, when it comes to volume, it is mid and startups," said Deepak.
In February this year, Dassault Systèmes launched the new "3D UNIV+RSES" technology that embed multiple generative AI technologies at the core of global IP Lifecycle Management (IPLM) for the benefit of its clients. This evolving architecture is aimed at helping clients to fully exploit their 3D design, virtual twins and PLM data in a new space of representation, the premier digital environment to train new categories of Experience as a Service (XaaS).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
DSM-Firmenich First Half 2025 Earnings: EPS: €1.94 (vs €0.16 in 1H 2024)
DSM-Firmenich (AMS:DSFIR) First Half 2025 Results Key Financial Results Revenue: €6.51b (up 3.4% from 1H 2024). Net income: €510.0m (up by €468.0m from 1H 2024). Profit margin: 7.8% (up from 0.7% in 1H 2024). The increase in margin was primarily driven by lower expenses. EPS: €1.94 (up from €0.16 in 1H 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period DSM-Firmenich Earnings Insights Looking ahead, revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Chemicals industry in Europe. Performance of the market in the Netherlands. The company's shares are down 7.8% from a week ago. Risk Analysis It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with DSM-Firmenich, and understanding this should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Results: Siemens Healthineers AG Beat Earnings Expectations And Analysts Now Have New Forecasts
A week ago, Siemens Healthineers AG (ETR:SHL) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. It was overall a positive result, with revenues beating expectations by 2.0% to hit €5.7b. Siemens Healthineers reported statutory earnings per share (EPS) €0.49, which was a notable 17% above what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. After the latest results, the 18 analysts covering Siemens Healthineers are now predicting revenues of €24.6b in 2026. If met, this would reflect a modest 5.4% improvement in revenue compared to the last 12 months. Per-share earnings are expected to climb 17% to €2.29. In the lead-up to this report, the analysts had been modelling revenues of €24.8b and earnings per share (EPS) of €2.34 in 2026. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts. See our latest analysis for Siemens Healthineers The consensus price target held steady at €59.86, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Siemens Healthineers, with the most bullish analyst valuing it at €65.00 and the most bearish at €50.00 per share. This is a very narrow spread of estimates, implying either that Siemens Healthineers is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Siemens Healthineers' past performance and to peers in the same industry. It's pretty clear that there is an expectation that Siemens Healthineers' revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 4.3% growth on an annualised basis. This is compared to a historical growth rate of 9.0% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 5.6% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Siemens Healthineers. The Bottom Line The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Siemens Healthineers. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Siemens Healthineers going out to 2027, and you can see them free on our platform here. And what about risks? Every company has them, and we've spotted 1 warning sign for Siemens Healthineers you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
41 minutes ago
- Yahoo
Befesa S.A. (ETR:BFSA) Just Released Its Half-Year Earnings: Here's What Analysts Think
Befesa S.A. (ETR:BFSA) came out with its half-yearly results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report. Revenues came in 2.8% below expectations, at €602m. Statutory earnings per share were relatively better off, with a per-share profit of €1.27 being roughly in line with analyst estimates. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. After the latest results, the ten analysts covering Befesa are now predicting revenues of €1.28b in 2025. If met, this would reflect a satisfactory 5.1% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to ascend 19% to €2.10. Yet prior to the latest earnings, the analysts had been anticipated revenues of €1.32b and earnings per share (EPS) of €2.05 in 2025. If anything, the analysts look to have become slightly more optimistic overall; while they decreased their revenue forecasts, EPS predictions increased and ultimately earnings are more important. Check out our latest analysis for Befesa The consensus has made no major changes to the price target of €35.40, suggesting the forecast improvement in earnings is expected to offset the decline in revenues next year. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Befesa analyst has a price target of €42.00 per share, while the most pessimistic values it at €28.00. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that Befesa's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 11% growth on an annualised basis. This is compared to a historical growth rate of 15% over the past five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 4.6% annually. So it's pretty clear that, while Befesa's revenue growth is expected to slow, it's still expected to grow faster than the industry itself. The Bottom Line The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Befesa following these results. They also downgraded Befesa's revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. Still, earnings per share are more important to value creation for shareholders. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. With that in mind, we wouldn't be too quick to come to a conclusion on Befesa. Long-term earnings power is much more important than next year's profits. We have forecasts for Befesa going out to 2027, and you can see them free on our platform here. And what about risks? Every company has them, and we've spotted 2 warning signs for Befesa you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
